• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Looking Into Penumbra's Recent Short Interest

    5/23/24 3:15:15 PM ET
    $PEN
    Medical/Dental Instruments
    Health Care
    Get the next $PEN alert in real time by email

    Penumbra's (NYSE:PEN) short percent of float has risen 9.46% since its last report. The company recently reported that it has 2.13 million shares sold short, which is 7.75% of all regular shares that are available for trading. Based on its trading volume, it would take traders 6.61 days to cover their short positions on average.

    Why Short Interest Matters

    Short interest is the number of shares that have been sold short but have not yet been covered or closed out. Short selling is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.

    Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.

    See Also: List of the most shorted stocks

    Penumbra Short Interest Graph (3 Months)

    short_fig

    As you can see from the chart above the percentage of shares that are sold short for Penumbra has grown since its last report. This does not mean that the stock is going to fall in the near-term but traders should be aware that more shares are being shorted.

    Comparing Penumbra's Short Interest Against Its Peers

    Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.

    According to Benzinga Pro, Penumbra's peer group average for short interest as a percentage of float is 4.07%, which means the company has more short interest than most of its peers.

    Did you know that increasing short interest can actually be bullish for a stock? This post by Benzinga Money explains how you can profit from it.

    This article was generated by Benzinga's automated content engine and was reviewed by an editor.

    Get the next $PEN alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $PEN

    DatePrice TargetRatingAnalyst
    12/18/2025$370.00Neutral → Overweight
    Analyst
    12/11/2025$350.00Neutral → Buy
    Citigroup
    11/18/2025$15.00Underweight
    Wells Fargo
    10/8/2025$326.00Hold → Buy
    Needham
    9/2/2025$300.00Outperform
    Evercore ISI
    3/14/2025$320.00Buy
    BofA Securities
    1/21/2025$305.00Buy
    UBS
    12/17/2024$275.00Outperform
    Oppenheimer
    More analyst ratings

    $PEN
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Penumbra upgraded by Analyst with a new price target

    Analyst upgraded Penumbra from Neutral to Overweight and set a new price target of $370.00

    12/18/25 8:43:06 AM ET
    $PEN
    Medical/Dental Instruments
    Health Care

    Penumbra upgraded by Citigroup with a new price target

    Citigroup upgraded Penumbra from Neutral to Buy and set a new price target of $350.00

    12/11/25 8:45:41 AM ET
    $PEN
    Medical/Dental Instruments
    Health Care

    Wells Fargo initiated coverage on Penumbra with a new price target

    Wells Fargo initiated coverage of Penumbra with a rating of Underweight and set a new price target of $15.00

    11/18/25 9:40:08 AM ET
    $PEN
    Medical/Dental Instruments
    Health Care

    $PEN
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    President Narayan Shruthi covered exercise/tax liability with 286 shares, decreasing direct ownership by 1% to 26,317 units (SEC Form 4)

    4 - Penumbra Inc (0001321732) (Issuer)

    1/16/26 7:50:05 PM ET
    $PEN
    Medical/Dental Instruments
    Health Care

    Director Grewal Harpreet sold $58,151 worth of shares (186 units at $312.64), decreasing direct ownership by 2% to 8,230 units (SEC Form 4)

    4 - Penumbra Inc (0001321732) (Issuer)

    1/8/26 9:06:21 PM ET
    $PEN
    Medical/Dental Instruments
    Health Care

    Director Wilder Thomas sold $57,794 worth of shares (186 units at $310.72), closing all direct ownership in the company (SEC Form 4)

    4 - Penumbra Inc (0001321732) (Issuer)

    1/6/26 7:33:35 PM ET
    $PEN
    Medical/Dental Instruments
    Health Care

    $PEN
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Boston Scientific announces results for fourth quarter and full year 2025

    MARLBOROUGH, Mass., Feb. 4, 2026 /PRNewswire/ -- Boston Scientific Corporation (NYSE:BSX) generated net sales of $5.286 billion during the fourth quarter of 2025, growing 15.9 percent on a reported basis, 14.3 percent on an operational1 basis and 12.7 percent on an organic2 basis, all compared to the prior year period. The company reported GAAP net income attributable to Boston Scientific common stockholders of $672 million or $0.45 per share (EPS), compared to $566 million or $0.38 per share a year ago, and achieved adjusted3 EPS of $0.80 for the period, compared to $0.70 a year ago.

    2/4/26 6:30:00 AM ET
    $BSX
    $PEN
    Medical/Dental Instruments
    Health Care

    Boston Scientific announces agreement to acquire Penumbra, Inc.

    Acquisition to expand Boston Scientific's cardiovascular portfolio and further address increasing prevalence of vascular diseases Provides scaled entry into mechanical thrombectomy and neurovascular, key strategic adjacencies Conference call at 8:00 a.m. ET to discuss details of the transaction MARLBOROUGH, Mass. and ALAMEDA, Calif., Jan. 15, 2026 /PRNewswire/ -- Boston Scientific Corporation (NYSE:BSX) and Penumbra, Inc., (NYSE:PEN) today announced the companies have entered into a definitive agreement under which Boston Scientific will acquire Penumbra in a cash and stock transaction that values Penumbra at $374 per share, reflecting an enterprise value of approximately $14.5 billion.i

    1/15/26 7:00:00 AM ET
    $BSX
    $PEN
    Medical/Dental Instruments
    Health Care

    Penumbra, Inc. Provides Preliminary Update on Fourth Quarter and Full Year 2025 Financial Results

    ALAMEDA, Calif., Jan. 15, 2026 /PRNewswire/ -- Penumbra, Inc. (NYSE:PEN), the world's leading thrombectomy company, today announced certain unaudited and preliminary financial results for the fourth quarter and full year 2025. Unaudited and Preliminary Financial Highlights: Fourth quarter 2025 revenue of $383.0 million to $384.8 million, which represents growth of approximately 21.4% to 22.0% compared to the fourth quarter of 2024.  Excluding the impact of the China region, revenue growth was approximately 23.2% to 23.8% for the fourth quarter 2025.Revenue of $1,401.3 million 

    1/15/26 7:00:00 AM ET
    $PEN
    Medical/Dental Instruments
    Health Care

    $PEN
    SEC Filings

    View All

    Amendment: SEC Form SCHEDULE 13G/A filed by Penumbra Inc.

    SCHEDULE 13G/A - Penumbra Inc (0001321732) (Subject)

    2/6/26 1:11:50 PM ET
    $PEN
    Medical/Dental Instruments
    Health Care

    Amendment: SEC Form SCHEDULE 13G/A filed by Penumbra Inc.

    SCHEDULE 13G/A - Penumbra Inc (0001321732) (Subject)

    2/5/26 1:31:51 PM ET
    $PEN
    Medical/Dental Instruments
    Health Care

    SEC Form 425 filed by Penumbra Inc.

    425 - Penumbra Inc (0001321732) (Subject)

    2/4/26 5:02:26 PM ET
    $PEN
    Medical/Dental Instruments
    Health Care

    $PEN
    Leadership Updates

    Live Leadership Updates

    View All

    New Survey Shows Management of Blood Clots is Inconsistent, Even for Patients with the Same Risk Profile

    Survey Conducted by the Get Out the Clot Campaign, an Initiative Focused on Identifying and Closing Gaps in Patient Care for Blood Clots ALAMEDA, Calif., Sept. 9, 2025 /PRNewswire/ -- The American Venous Forum (AVF), International Society on Thrombosis and Haemostasis (ISTH), National Blood Clot Alliance (NBCA), Penumbra (NYSE:PEN), The PERT Consortium® and Society for Vascular Medicine (SVM), which have come together to form the Get Out the Clot campaign, today announced findings from a new survey assessing the current state of venous thromboembolism (VTE) care, also known as blood clots in the body. Get Out the Clot is a collaborative educational initiative to help identify gaps in patient

    9/9/25 9:00:00 AM ET
    $PEN
    Medical/Dental Instruments
    Health Care

    Get Out the Clot Campaign Brings Together Leaders and Experts to Improve Patient Care for Venous Thromboembolism

    Campaign is led by prominent medical societies to minimize discrepancies in treating blood clot conditions, such as in pulmonary embolism, where there are often delays in care (up to 26% of patients in one study) and misdiagnosis (up to 53% of patients in one study)1,2 ALAMEDA, Calif., Oct. 10, 2024 /PRNewswire/ -- The International Society on Thrombosis and Haemostasis (ISTH), National Blood Clot Alliance (NBCA), Penumbra, Inc. (NYSE:PEN), The PERT Consortium™ and Society for Vascular Medicine (SVM) today announced the launch of the Get Out the Clot campaign in advance of World Thrombosis Day on October 13. The campaign is a collaborative educational initiative focused on identifying gaps i

    10/10/24 9:00:00 AM ET
    $PEN
    Medical/Dental Instruments
    Health Care

    Omniscient Neurotechnology Appoints Two New Members to Its Board of Directors

    SYDNEY, Australia, Oct. 24, 2022 (GLOBE NEWSWIRE) -- Omniscient Neurotechnology, the brain mapping company creating new possibilities in brain health, today announced the appointment of Barbara Nelson and Surbhi Sarna to its board of directors. Both appointees are visionaries across the biotech, healthcare and technology industries and bring a unique perspective to the company's corporate strategy and growth. They, along with the existing board members, will strategically guide Omniscient as it develops products that unlock new insights into advanced brain care. "Omniscient is a global leader in connectomics, but we have much work ahead of us to scale to our full potential," said Chairma

    10/24/22 8:30:00 AM ET
    $BLZE
    $GSIT
    $PEN
    Computer Software: Prepackaged Software
    Technology
    Semiconductors
    Medical/Dental Instruments

    $PEN
    Financials

    Live finance-specific insights

    View All

    Boston Scientific announces results for fourth quarter and full year 2025

    MARLBOROUGH, Mass., Feb. 4, 2026 /PRNewswire/ -- Boston Scientific Corporation (NYSE:BSX) generated net sales of $5.286 billion during the fourth quarter of 2025, growing 15.9 percent on a reported basis, 14.3 percent on an operational1 basis and 12.7 percent on an organic2 basis, all compared to the prior year period. The company reported GAAP net income attributable to Boston Scientific common stockholders of $672 million or $0.45 per share (EPS), compared to $566 million or $0.38 per share a year ago, and achieved adjusted3 EPS of $0.80 for the period, compared to $0.70 a year ago.

    2/4/26 6:30:00 AM ET
    $BSX
    $PEN
    Medical/Dental Instruments
    Health Care

    Boston Scientific announces agreement to acquire Penumbra, Inc.

    Acquisition to expand Boston Scientific's cardiovascular portfolio and further address increasing prevalence of vascular diseases Provides scaled entry into mechanical thrombectomy and neurovascular, key strategic adjacencies Conference call at 8:00 a.m. ET to discuss details of the transaction MARLBOROUGH, Mass. and ALAMEDA, Calif., Jan. 15, 2026 /PRNewswire/ -- Boston Scientific Corporation (NYSE:BSX) and Penumbra, Inc., (NYSE:PEN) today announced the companies have entered into a definitive agreement under which Boston Scientific will acquire Penumbra in a cash and stock transaction that values Penumbra at $374 per share, reflecting an enterprise value of approximately $14.5 billion.i

    1/15/26 7:00:00 AM ET
    $BSX
    $PEN
    Medical/Dental Instruments
    Health Care

    Penumbra, Inc. Reports Third Quarter 2025 Financial Results

    ALAMEDA, Calif., Nov. 5, 2025 /PRNewswire/ -- Penumbra, Inc. (NYSE:PEN), the world's leading thrombectomy company, today reported financial results for the third quarter ended September 30, 2025. Revenue of $354.7 million in the third quarter of 2025, an increase of 17.8% or 16.9% in constant currency1, compared to the third quarter of 2024.Total U.S. revenue of $275.0 million in the third quarter of 2025, an increase of 21.5% compared to the third quarter of 2024.U.S. Thrombectomy revenue of $192.0 million in the third quarter of 2025, an increase of 18.5% compared to the thi

    11/5/25 4:05:00 PM ET
    $PEN
    Medical/Dental Instruments
    Health Care

    $PEN
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Penumbra Inc.

    SC 13G/A - Penumbra Inc (0001321732) (Subject)

    11/14/24 1:22:36 PM ET
    $PEN
    Medical/Dental Instruments
    Health Care

    Amendment: SEC Form SC 13G/A filed by Penumbra Inc.

    SC 13G/A - Penumbra Inc (0001321732) (Subject)

    11/12/24 12:53:28 PM ET
    $PEN
    Medical/Dental Instruments
    Health Care

    SEC Form SC 13G filed by Penumbra Inc.

    SC 13G - Penumbra Inc (0001321732) (Subject)

    2/14/24 10:03:02 AM ET
    $PEN
    Medical/Dental Instruments
    Health Care